FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions

Azurity Pharmaceuticals has announced a breakthrough in the treatment landscape for chronic myeloid leukemia (CML). The FDA has approved Danziten™, the first and only nilotinib formulation that removes the strict fasting requirements traditionally required with similar therapies.